1. |
Barriers to warfarin use in atrial fibrillation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
2. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
4. |
Enoxaparin sodium - favourable alternative to heparin? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 5-6
Carmen Innes,
Preview
|
|
摘要:
Two recent studies have shown that enoxaparin sodium appears to be a favourable alternative to heparin for treating deep vein thrombosis (DVT) and reducing the risk of venous thromboembolism (VTE). In the first study, the efficacy, tolerability and overall costs of enoxaparin sodium and IV heparin in the treatment of DVT were similar, yet researchers recommended enoxaparin sodium due to its ease of administration, avoidance of IV catheters and decreased need for laboratory monitoring. In the second study, enoxaparin sodium resulted in a significantly lower incidence of thromboembolic events plus mortality, and a lower incidence of bleeding events, compared with unfractionated heparin (UFH), in hospitalised patients at increased risk for thromboembolism. And a related study demonstrated that thromboprophylaxis guidelines are not being adhered to as well as they could be - 1 in 6 cases of VTE occurring over a 1-year period were found to be preventable. The studies were presented at the 41st Annual Meeting of the American Society of Hematology [New Orleans, US; December 1999].
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
5. |
Thrombolysis with alteplase preferable to standard stroke therapy? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
6. |
Sulbactam/ampicillin dominates cefoxitin in acute PID |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
7. |
Niravoline improves diuresis in patients with cirrhosis |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|
10. |
Trastuzumab plus chemotherapy combination gains ground |
|
Inpharma Weekly,
Volume &NA;,
Issue 1224,
2000,
Page 11-12
Robert Carlson,
Preview
|
|
摘要:
Women with metastatic breast cancer whose tumours overexpress the HER-2/Neu protein have more aggressive disease and shortened survival duration. Trastuzumab ['Herceptin'], a humanised anti-HER2/Neu monoclonal antibody, has demonstrated activity as a single agent in previously untreated patients with metastatic breast cancer - a recent trial demonstrated a 15% overall response rate.1*Researchers are now combining trastuzumab with other, more traditional chemotherapeutic drugs that have single-agent activity in this disease. In another recent trial, when trastuzumab plus chemotherapy (paclitaxel or a combination of anthracyclines plus cyclophosphamide) was compared with chemotherapy alone in women with previously untreated metastatic breast cancer, the trastuzumab combination regimen demonstrated a superior response rate and survival duration.2**At the 22nd Annual Breast Cancer Symposium [San Antonio, Texas; December 1999] researchers presented data from their most recent trials using trastuzumab in combination with docetaxel, vinorelbine or paclitaxel, all of which have well established activity in advanced breast cancer.
ISSN:1173-8324
出版商:ADIS
年代:2000
数据来源: ADIS
|